CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma – Targeted Oncology
Targeted Oncology |
CAR T-Cells in the Treatment Landscape of Mantle Cell Lymphoma
Targeted Oncology Owen O’Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL … |
Labiotech.eu (blog) |
Bluebird Bio’s Gets Positive Results For Beta-Thalassemia Gene …
Labiotech.eu (blog) bluebird bio, a Swiss-US firm, has obtained interim data from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. Gene Therapy for Thalassemia Shows PromiseNorthwestern University NewsCenter A Gene Therapy, Successful In Beta-Thalassemia, Might Lead To …Health Thoroughfare Bluebird Bio One Step Closer to First Approved DrugPharmaLive (press release) Motley Fool –Brinkwire (press release) all 7 news articles » |
Medical Xpress |
Synthetic biology approaches to improving immunotherapy
Medical Xpress The AACR 2018 Meeting in Chicago is ending today and has featured the major new results in cancer treatment and immunotherapy treatments in particular. Immunotherapy, the use of the patient’s own immune system to attack their cancer, has become a hot … |